Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Follow-Up Questions
Qui est le CEO de Omeros Corp ?
Dr. Gregory Demopulos est le Chairman of the Board de Omeros Corp, il a rejoint l'entreprise depuis 1994.
Quelle est la performance du prix de l'action OMER ?
Le prix actuel de OMER est de $8.12, il a increased de 0.18% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Omeros Corp ?
Omeros Corp appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Omeros Corp ?
La capitalisation boursière actuelle de Omeros Corp est de $552.6M
Est-ce que Omeros Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Omeros Corp, y compris 3 achat fort, 5 achat, 3 maintien, 0 vente et 3 vente forte
